Skip to main content
    P

    Protagenic Therapeutics Inc (PTIXW)

    Official site

    BIOTECHNOLOGY

    $0.00
    +0.00 (+0.00%)

    Last updated: Apr 24, 2026 at 5:00 PM ET

    Protagenic Therapeutics Inc (PTIXW) Financials: Revenue, Profit and Cash Flow

    Updated Dec 31, 2025. Financial statements from company filings, amounts in US dollars.

    For the fiscal year ended Dec 31, 2025, net income was -$5.16M, operating cash flow was -$4.14M and free cash flow was -$4.14M. The quarter ended Dec 31, 2025 had net income of $2.21M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025N/AN/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Dec 2025, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Cost of revenue$37.72K$50.29K$28.22K$30N/A$286$339$347$148$534
    Gross profit-$37.72K-$50.29K-$28.22K-$30N/A-$286-$339-$347-$148-$534
    Research and development$1.70M$3.85M$3.32M$1.59M$1.14M$699.80K$807.95K$881.19K$717.45K$417.87K
    Operating income-$5.83M-$5.70M-$4.53M-$3.56M-$4.14M-$2.55M-$2.09M-$2.31M-$2.37M-$2.23M
    Net income-$5.16M-$5.53M-$5.00M-$3.56M-$4.52M-$2.55M-$1.75M-$2.56M-$2.26M-$2.28M
    EBITDAN/A-$5.47M-$4.50M-$3.42M-$4.14M-$2.55M-$2.09M-$2.31M-$2.37MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    RevenueN/A$0$0$0-$25.14K$25.14K$0$3.20K$0$0$0$0
    Gross profitN/A-$12.57K-$12.57K-$12.57K-$50.29K-$12.57K-$12.57K-$12.57KN/A-$1.42K-$91-$30
    Operating income-$925.10K-$1.11M-$2.34M-$1.45M-$1.64M-$652.00K-$1.67M-$1.74M-$1.21M-$1.43M-$1.14M-$739.00K
    Net income$2.21M-$869.50K-$5.06M-$1.44M-$1.55M-$641.00K-$1.61M-$1.72M-$1.68M-$1.40M-$1.21M-$718.00K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $3.16M exceeded cash and equivalents by $943.26K. Shareholder equity was negative, at -$4.69M, as total liabilities of $6.82M exceeded total assets of $2.13M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$2.13M$1.96M$4.32M$8.04M$11.06M$879.25K$842.27K$696.88K$1.78M$3.16M
    Current assets$2.30M$1.88M$4.20M$8.04M$11.06M$879.25K$841.98K$696.27K$1.78M$3.16M
    Cash and equivalents$2.21M$1.84M$1.29M$215.19K$541.17K$671.09K$798.62K$362.49K$399.69K$3.10M
    Total liabilities$6.82M$942.76K$655.25K$1.12M$1.12M$2.03M$1.48M$907.77K$561.69K$684.86K
    Short-term debt$3.16MN/AN/A$344.23K$186.15KN/AN/AN/AN/AN/A
    Long-term debtN/AN/AN/AN/A$318.43K$1.37M$279.37KN/AN/AN/A
    Shareholder equity-$4.69M$1.01M$3.67M$6.92M$9.94M-$1.15M-$634.37K-$210.88K$1.22M$2.48M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total assets$2.13M$2.14M$6.49M$988.65K$1.96M$1.51M$1.47M$2.58M$4.32M$5.43M$6.92M$7.67M
    Total liabilities$6.82M$9.70M$10.46M$1.08M$942.76K$789.32K$674.56K$446.10K$655.25K$1.28M$1.51M$1.25M
    Cash and equivalents$2.21M$2.72M$4.10M$872.96K$1.84M$1.06M$924.60K$831.78K$1.29M$153.33K$219.44K$138.49K
    Shareholder equity-$4.69M-$4.70M-$3.97M-$88.33K$1.01M$719.01K$792.52K$2.13M$3.67M$4.15M$5.41M$6.41M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$4.14M-$4.22M-$3.70M-$1.99M-$2.80M-$1.35M-$487.99K-$1.07M-$1.38M-$1.14M
    Capital expenditures$3$0$149.78K$1.80K$4$0$0$0$0$0
    Free cash flow-$4.14M-$4.22M-$3.85M-$2.00M-$2.80M-$1.35M-$487.99K-$1.07M-$1.38M-$1.14M
    Investing cash flow$943.18K$2.80M$4.78M$1.60M-$9.91MN/A$250.00K$1.05M-$1.29MN/A
    Financing cash flow$4.51M$1.96M$0$0$12.58M$1.22M$670.00KN/A$0$4.28M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow-$410.42K-$1.49M-$1.17M-$1.07M-$819.79K-$185.66K-$1.55M-$1.66M-$1.14M-$655.77K-$1.53M-$371.83K
    Capital expenditures$6$3$3$3$0$0$0$5$93.97K$55.81K$0$1.80K
    Free cash flow-$410.43K-$1.49M-$1.17M-$1.07M-$819.79K-$185.66K-$1.55M-$1.66M-$1.24M-$711.57K-$1.53M-$373.64K
    Last 12 quarters

    Frequently Asked Questions About PTIXW

    Is Protagenic Therapeutics profitable?

    No. Protagenic Therapeutics reported net income of -$5.16M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PTIXW generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$4.14M minus capital expenditures of $3 produced free cash flow of -$4.14M.

    How much debt does Protagenic Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $3.16M and cash and equivalents of $2.21M.